Future Newborns with Opioid-Induced Neonatal Abstinence Syndrome (NAS) Could Be Assessed with the Genetic Addiction Risk Severity (GARS) Test and Potentially Treated Using Precision Amino-Acid Enkephalinase Inhibition Therapy (KB220) as a Frontline Modality Instead of Potent Opioids

Mauro Ceccanti, Kenneth Blum, Abdalla Bowirrat, Catherine A. Dennen, Eric R. Braverman, David Baron, Thomas Mclaughlin, John Giordano, Ashim Gupta, Bernard W. Downs, Debasis Bagchi, Debmalya Barh, Igor Elman, Panayotis K. Thanos, Rajendra D. Badgaiyan, Drew Edwards, Mark S. Gold

Open source

DOI: 10.3390/jpm12122015
Published: 2022-12-06
Container: Journal of Personalized Medicine
Publisher: MDPI AG
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.3390/jpm12122015,
  title = {Future Newborns with Opioid-Induced Neonatal Abstinence Syndrome (NAS) Could Be Assessed with the Genetic Addiction Risk Severity (GARS) Test and Potentially Treated Using Precision Amino-Acid Enkephalinase Inhibition Therapy (KB220) as a Frontline Modality Instead of Potent Opioids},
  author = {Mauro Ceccanti and Kenneth Blum and Abdalla Bowirrat and Catherine A. Dennen and Eric R. Braverman and David Baron and Thomas Mclaughlin and John Giordano and Ashim Gupta and Bernard W. Downs and Debasis Bagchi and Debmalya Barh and Igor Elman and Panayotis K. Thanos and Rajendra D. Badgaiyan and Drew Edwards and Mark S. Gold},
  year = {2022},
  journal = {Journal of Personalized Medicine},
  doi = {10.3390/jpm12122015},
  url = {https://doi.org/10.3390/jpm12122015}
}

RIS

TY  - JOUR
TI  - Future Newborns with Opioid-Induced Neonatal Abstinence Syndrome (NAS) Could Be Assessed with the Genetic Addiction Risk Severity (GARS) Test and Potentially Treated Using Precision Amino-Acid Enkephalinase Inhibition Therapy (KB220) as a Frontline Modality Instead of Potent Opioids
AU  - Mauro Ceccanti
AU  - Kenneth Blum
AU  - Abdalla Bowirrat
AU  - Catherine A. Dennen
AU  - Eric R. Braverman
AU  - David Baron
AU  - Thomas Mclaughlin
AU  - John Giordano
AU  - Ashim Gupta
AU  - Bernard W. Downs
AU  - Debasis Bagchi
AU  - Debmalya Barh
AU  - Igor Elman
AU  - Panayotis K. Thanos
AU  - Rajendra D. Badgaiyan
AU  - Drew Edwards
AU  - Mark S. Gold
PY  - 2022
JO  - Journal of Personalized Medicine
DO  - 10.3390/jpm12122015
UR  - https://doi.org/10.3390/jpm12122015
ER  -

APA

Ceccanti, M., Blum, K., Bowirrat, A., Dennen, C. A., Braverman, E. R., Baron, D., Mclaughlin, T., Giordano, J., Gupta, A., Downs, B. W., Bagchi, D., Barh, D., Elman, I., Thanos, P. K., Badgaiyan, R. D., Edwards, D., & Gold, M. S. (2022). Future Newborns with Opioid-Induced Neonatal Abstinence Syndrome (NAS) Could Be Assessed with the Genetic Addiction Risk Severity (GARS) Test and Potentially Treated Using Precision Amino-Acid Enkephalinase Inhibition Therapy (KB220) as a Frontline Modality Instead of Potent Opioids. Journal of Personalized Medicine. https://doi.org/10.3390/jpm12122015

Source records

crossref · retrieved 2026-11-09T06:42:00.990Z